GTS Securities’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

GTS Securities’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,833	Closed	-$799K	–	4193
2023 Q2	$799K	Buy	+7,833	New	+$741K	0.03%	498

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GTS Securities's RETA Position: Q3 2023 in Review

GTS Securities sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,833 shares — an estimated $799K sold.

GTS Securities first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $799K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

GTS Securities reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
GTS Securities sold 7,833 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $799K.
GTS Securities first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
GTS Securities's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $799K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on GTS Securities's 13F filing for Q3 2023, filed 15 Nov 2023.